They used trastuzumab and lapatinib dual-targeted therapy to treat 27 patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer. The results showed that the objective response rate was 30% (CR 4%, PR 26%), 44% of patients had stable disease, 48% (13/27) of patients developed rash (1 patient had a grade 3 rash), and there were no treatment-related grade 4 and 5 adverse events. This evidence concerns the gene ERBB2 and metastatic colorectal cancer.